26 марта, 08:22

BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound?

BioMarin Pharmaceutical (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
Выбор редакции
12 марта, 12:40

Alnylam Pharmaceuticals (ALNY) Up 1.6% Since Earnings Report: Can It Continue?

Alnylam Pharmaceuticals (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
28 февраля, 07:00

Henri Termeer’s legacy is a vibrant biotech sector

Former Genzyme chief helped make ‘orphan’ drugs viable

23 февраля, 17:12

BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

09 февраля, 17:54

Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates

Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.

07 февраля, 18:43

Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

08 ноября 2017, 19:47

Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

02 ноября 2017, 16:34

Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak

Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.

Выбор редакции
27 октября 2017, 18:30

BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

29 сентября 2017, 16:13

Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat

Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.

28 сентября 2017, 16:23

Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak

Sanofi's (SNY) Genzyme and Vaccines units are driving sales. Sales from the Diabetes franchise however continue to drop.

11 июля 2017, 23:19

Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

08 июня 2017, 16:47

BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
08 июня 2017, 10:31

Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

30 мая 2017, 16:01

Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

Выбор редакции
Выбор редакции
08 мая 2017, 20:59

Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

05 мая 2017, 17:37

Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents